QurAlis Grants Lilly Exclusive Global License For QRL-204, A Precision Therapy That Restores UNC13A Function In ALS And FTD For An Upfront Payment Of $45M, Plus An Additional Equity Investment. QurAlis Is Also Eligible For Future Milestone Payments Of Up To $577M And Tiered Royalties On Net Sales
Portfolio Pulse from Benzinga Newsdesk
QurAlis has granted Eli Lilly an exclusive global license for QRL-204, a precision therapy aimed at restoring UNC13A function in ALS and FTD. The collaboration will leverage QurAlis' expertise in ALS and ASO development to advance QRL-204 and next-generation compounds.
June 03, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly has secured an exclusive global license for QRL-204, a precision therapy for ALS and FTD, from QurAlis. This partnership will leverage QurAlis' expertise to advance QRL-204 and next-generation compounds.
The exclusive global license for QRL-204 represents a significant addition to Eli Lilly's portfolio, potentially enhancing its position in the neurodegenerative disease market. The collaboration with QurAlis could accelerate the development and commercialization of QRL-204, positively impacting Eli Lilly's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100